Drug intelligence / Profile preview

NUTROF TOTAL

Development stage: Phase 3
Lead developer: Théa Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

NUTROF TOTAL is an oral multi-ingredient dietary supplement developed by Thea Pharmaceuticals for the maintenance of vision and nutritional support of patients with age-related macular degeneration (AMD). Formulated by nutritionists and ophthalmologists, it contains a combination of macular carotenoids (lutein and zeaxanthin), omega-3 fatty acids (EPA and DHA), resveratrol, and antioxidant vitamins and minerals (Vitamins C, E, D3, Zinc, Copper, and Selenium). The formulation is designed to align with AREDS 2 study recommendations. Its components work synergistically to filter blue light, reduce oxidative stress in the retina, and provide anti-inflammatory and anti-angiogenic effects to support macular health.

Brand names: NUTROF TOTAL
Other names: Nutrof Total

Beyond the preview

Go deeper on NUTROF TOTAL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NUTROF TOTAL.

Explore the full profile